Infectious diseases are usually caused by pathogenic microorganisms such as bacteria, viruses, fungi, and parasites. These diseases are transmitted from one individual to the other through direct or indirect contact. Anti-infective drugs inhibit the growth of such diseases. These drugs act through a mechanism of host defense system which directly targets the causative agent. Infectious diseases such as malaria, HIV, tuberculosis, influenza, hepatitis A, and hepatitis C are the major diseases causing majority of deaths in the world. Infectious diseases are caused due to poor sanitation and inadequate or improper personal hygiene. Anti-infective drugs are used to inhibit or prevent the growth of disease-causing agents. Antibacterial, antifungal, antiparasitic, and antiviral drugs are some of the anti-infective drugs used for the treatment of infectious diseases.
Major driving factors of the global infectious disease therapeutics market are favorable reimbursement policies for infectious diseases, increasing incidence of infectious diseases, escalating consumption of anti-microbial direct acting drugs, growing geriatric population, rising awareness among population, upsurge in government investment into healthcare to eradicate infectious diseases, and also growing number of people affected with cancer which weakens the immunity system, thereby attracting various infectious diseases. However, expiration of patent for branded drugs is anticipated to increase the use of generic low-quality drugs which is a major restraining factor of the growth of the global infectious disease therapeutic market.
The global infectious disease therapeutics market can be segmented into mode of treatment, by target organism, by infection type, by distribution channel, and by geography. By mode of treatment, the global infectious diseases therapeutics market can be categorized into drugs and vaccines. The drugs segment can be further classified into oral, topical, injection, and other. By target organism, the global infectious diseases market can be divided into anti-bacterial, anti-fungal, antiviral, anti-parasitic, and others. According to infection type, the global infectious disease therapeutics market can be classified into HIV/AIDS, influenza, hepatitis, malaria, tuberculosis, and others. In terms of distribution channel, the global infectious disease therapeutics market can be bifurcated into online pharmacies, retail pharmacies, hospital pharmacies, and others. By geography, the global infectious disease therapeutics market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of mode of treatment, the drugs segment dominates the global infectious disease therapeutic market. By target organism, segment the anti-viral and anti-bacterial segments dominate the global infectious disease therapeutics market. Based on infection type, increasing prevalence of all diseases dominates the growth of the market. The incidence of infectious diseases varies according to age and race.
In terms of geography, the global infectious diseases therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe dominate the global infectious disease therapeutics market. Presence of a large number of pharmaceutical manufacturers, favorable reimbursement policies, and rising healthcare expenditure with increasing awareness regarding healthy lifestyle drive the growth of the global infectious disease therapeutics market in these two regions. Rising incidence of infectious diseases due to poor sanitary facilities, large population, and increasing investment by healthcare companies for adequate availability of drugs are the major factors driving the growth of the infectious disease therapeutics market in Asia Pacific. Latin America and Middle East & Africa are the emerging markets for infectious disease therapeutics due to the large patient pool and rising awareness regarding healthcare in the regions.
Top players operating in the global infectious disease therapeutics market are F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Novartis AG, AbbVie, Inc., Astellas Pharma, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cubist, Eli Lilly and Company, Sanofi, and others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.